Although PFOA can cross the blood–brain barrier, its levels in the brains of Australian dementia patients (0.002 μM) were 8–10-fold lower than in the serum (0.016 μM) [66], indicating a potentially low risk of neurological disorders and ADGRL1 dysfunction. Here, ADGRL1 is linked to nervous system disorder.